Ludwig Burger, Emilio Parodi

(Reuters). Several sources have said that governments are preparing to accept COVID-19. However, they’re questioning whether to rely too heavily on drugmakers for adaptations of vaccines in order to prevent new virus variations. This is amid tensions between regulators and pharmaceutical companies.

Some experts believe that government agencies should help to develop new COVID vaccines and encourage innovation by smaller companies, just as they have done with current vaccines.

Dr. Larry Corey is a virologist responsible for overseeing the U.S.-funded COVID vaccine trial trials.

BioNTech Pfizer (NYSE:) The inventor of the most popular COVID vaccine in the west, he recently clashed against European Medicines Agency, (EMA), over which strategy to use for developing a vaccine that will fight the Omicron variant. Two sources who are familiar with the situation told Reuters.

According to an EMA spokesperson, the agency and other regulators encourage companies to investigate vaccines that can target multiple variants.

BioNTech, Pfizer and others began testing the vaccine for Omicron. They believe that it’s best to focus on one new major variant at a particular time.

After the record-breaking rise in infection rates, Omicron was discovered late last year.

Sources said that EMA regulators pressed drug manufacturers to grant equal priority to a vaccine which targets multiple variants. They believed this would give greater protection against future mutations. Sources said that EMA wouldn’t signal whether current vaccine trials would be sufficient to justify approval, even if companies show safety and immunity.

BioNTech announced Wednesday that the two companies will expand their trials to include Omicron as well as the original coronavirus.

BioNTech announced that they have decided to try a mixture shot to scientifically confirm decisions regarding the most appropriate vaccine strategy in the immediate future.

BioNTech declined to comment on discussions between the company and EMA. Pfizer representatives did not respond when asked.

Moderna (NASDAQ:) Inc has enjoyed success with COVID vaccine and is currently testing a shot against Omicron. It hopes to make it available in the fall.

Jacqueline Miller (top Moderna scientist) stated that this could lead to “the best breadth of protection” at a company function this month.

GlaxoSmithKline (NYSE 🙂 has also partnered with German biotech CureVac to develop a vaccine against multiple coronavirus types.

“WE MUST DO BETTER”

European and American public health officials want better tools for fighting COVID. The current vaccines have been shown to be very effective in preventing severe diseases and deaths, as well as transmission. Immunity levels can also decline within months.

Health officials are questioning whether vaccine companies, who have already reaped billions of dollars through first-generation COVID shots but stand to continue earning billions with repeated boosters, will spend that money on new vaccines providing longer-lasting and more effective protection. That could be a long-term investment.

Pfizer, BioNTech and others claim that their scientific research guides them in making decisions.

Smaller companies may be able to develop innovative approaches, and they might need financing for their early work. Corey from Seattle’s Fred Hutchinson Cancer Center said that.

“We have to improve, and we must fund it,” Corey added, noting that $2 billion could go towards funding a new COVID-vaccination generation. In a huge deal valued at 35 billion euro ($39.04 million), the European Union placed a large bet on future Pfizer/ BioNTech shots. The agreement calls for drug manufacturers to revise the shots in order to handle new versions.

EU members have expressed an interest in multiple versions of shots. According to one source, the messages sent to the companies were “give us more options”. Funding for early research on some vaccines was done by the international Coalition for Epidemic Preparedness Innovations. The Coalition has 200 million dollars available for research for the next generation of vaccines. Small grants have been granted to several manufacturers, including MigVax from Israel and DIOSynVax UK.

Pfizer is the western COVID vaccine maker, while BioNTech appears to be farthest along with redesigning their shots.

They launched a clinical study in January to test the immune response of Omicron vaccine recipients in both fully-vaccinated and unvaccinated individuals. Expected results are in April.

BioNTech argued that other laboratory tests showed Omicron exposure in people who have been vaccinated previously results in a wide immune response to major coronavirus variants.

They also said that lab tests on a BioNTech/Pfizer vaccine targeting Alpha and Delta versions yielded an inferior immune response to one-variant shots.

GSK stated that a combination vaccine can cause additional problems, such as exacerbating side effects experienced with the current shot. GSK stated that it is working to reduce the dosage in order to prevent this from compromising efficacy.

(Additional reporting by Francesco Guarascio at Brussels, Julie Steenhuysen at Chicago, Jennifer Rigby London, Bill Berkrot; Editing by Michele Gershberg et al.